Bisantrene and COVID-19 Coronavirus, page-31

Found this on the net.

In other ASX corporate news today:

One of the hottest performing anti-cancer biotechs, Race Oncology (ASX:RAC), raised $1.8m from health investor Merchant Opportunities Fund. The company says it now has sufficient resources to last the year. Despite shares being issued at a 9 per cent discount, shares spiked 6 per cent.

(https://unauthorised investment advice/news/corporate-eagle-health-pounces-on-another-coronavirus-opportunity/)
www.stock head.com.au

“To have attracted such strong support from a successful biotech institutional investor with a proven track record of picking promising early-stage life sciences companies is a significant validation of Race’s plans and future potential. We thank Merchant for their support and are now funded to progress our ‘five-path’ clinical strategy for Bisantrene,” said Peter Molloy, chief executive officer of Race.

https://*********.com.au/race-oncology-raises-1-8m-advance-five-path-strategy-cancer-drug-bisantrene/

Regards

Rossi70